NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Retrieved on: 2022-11-29 09:39:21

Tags for this article:

Click the tags to see associated articles and topics

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance. View article details on hiswai:

Excerpt

Details: Category: Antibodies: Published on Tuesday, 29 November 2022 10:27 ... NP137 is a humanized monoclonal antibody of isotype IgG1 directed ...

Article found on: pipelinereview.com